Gray‑market copies of Lilly’s obesity drug retatrutide show weaker weight‑loss results, study finds

A recent study examined the effectiveness of gray‑market versions of Eli Lilly’s triple‑agonist obesity drug retatrutide.

The analysis found that patients using these unapproved copies experienced noticeably less weight loss compared to those receiving the branded formulation.

Retatrutide has been highlighted in Phase 3 trials as one of the most potent obesity treatments, achieving up to 25 % body‑weight reduction in controlled studies.

The findings raise concerns about the quality and efficacy of counterfeit or off‑label products circulating in the market and underscore the importance of using approved medications.